New
HealthMore in Health→
Researchers argue mantle cell lymphoma treatment should start with tumor biology
Key Takeaways
- A new Lancet Haematology article argues mantle cell lymphoma should be treated according to biological risk at diagnosis.
- The authors highlight TP53 changes, Ki-67, and blastoid morphology as key high-risk markers.
- The proposed shift could intensify care for aggressive cases while avoiding unnecessary treatment for indolent disease.
DE
DT Editorial Team··via medicalxpress.com
